Profile: Rockwell Medical Inc (RMTI.OQ)
4.98USD
1 Aug 2013
$-0.07 (-1.39%)
$5.05
$5.08
$5.08
$4.83
119,940
214,509
$9.50
$3.16
Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., incorporated in 1996, manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, the Company was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
The Company’s drug development product, soluble ferric pyrophosphate (SFP), is for iron supplementation, a key element in the formation of new red blood cells. Iron supplementation is routinely administered to more than 90% of patients receiving treatment for anemia. It has licensed a drug therapy, SFP, for the delivery of iron supplementation for anemic dialysis patients. During 2011, Hemodialysis concentrates, which accounted for over 94% of its revenue, were comprised of two primary product types, which are described as acidified dialysate concentrate, also known as acid concentrate, and bicarbonate.
Renal Pure & CitraPure Liquid Acid Concentrate
Acid concentrate generally contains either citric acid or acetic acid, along with sodium chloride, dextrose and electrolyte additives, such as magnesium, potassium, and calcium. Acid concentrate products are manufactured in three basic series to reflect the dilution ratios used in various types of dialysis machines. It supplies all three series and manufactures approximately 60 different liquid acid concentrate formulations. The Company supplies liquid acid concentrate in both 55 gallon drums and in cases containing four one gallon containers. Its acetate-free, citric-acid concentrate includes citrate, which acts as an anticoagulant.
Dri-Sate Dry Acid Concentrate & Mixing System
The Company has 510(k) clearance from the United States Food & Drug Administration to market Dri-Sate Dry Acid Concentrate and its Dri-Sate Mixer. The Company’s Dri-Sate Dry Acid Concentrate and Dri-Sate Mixer allow a clinic to mix its acid concentrate on-site. The clinical technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to 50 or 100 gallons of purified water. Once mixed, the product is equivalent to the acid concentrate provided to its customers in liquid form.
RenalPure Powder Bicarbonate Concentrate
Bicarbonate is sold in powder form and each clinic mixes bicarbonate onsite as required. It offers nine different bicarbonate powder products covering all three series of generally used bicarbonate dilution ratios.
SteriLyte Liquid Bicarbonate Concentrate
The Company has 510(k) clearance from the United States Food & Drug Administration to market liquid bicarbonate, which it sells under the name SteriLyte Liquid Bicarbonate. Its SteriLyte Liquid Bicarbonate is used in both acute care and chronic care settings.
Ancillary Products
The Company offers a range of ancillary products. These products include blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers.
SFP Iron Therapy
The Company has licensed the right to manufacture and sell SFP. During 2011, it started its Phase III clinical program for SFP.
The Company competes with Fresenius Medical Care AG& Co. KGaA and Minntech Corporation.
Company Address
Rockwell Medical Inc
30142 Wixom Road
WIXOM MI 48393
P: +1248.9609009
F: +1248.9609119
Company Web Links
| Name | Compensation |
|---|---|
Robert Chioini |
1,912,780 |
Thomas Klema |
880,590 |
Ajay Gupta |
1,200,260 |
Raymond Pratt |
-- |
Patrick Bagley |
-- |
- Rockwell Medical's iron deficiency drug succeeds in trial
- Rockwell Medical's iron deficiency drug succeeds in trial
- Rockwell Medical reports positive data on iron deficiency drug
- UPDATE 1-Rockwell Medical reports positive data on iron deficiency drug
- BRIEF-Rockwell Medical jumps 24 percent in premarket

